Inotropes and vasopressors:Review of physiology and clinical use in cardiovascular disease

Circulation

Volumn 118, Issue 10, 2008, Pages 1047-1056

  Overgaard, Christopher B ^a   Džavík, Vladimír ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Drugs; Heart failure; Inotropic agents; Shock; Vasopressin

Indexed keywords

ADRENALIN; AMRINONE; ATROPINE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; HYPERTENSIVE AGENT; INOTROPIC AGENT; ISOPRENALINE; LEVOSIMENDAN; MILRINONE; NITRATE; NORADRENALIN; PHENYLEPHRINE; SILDENAFIL; VASOPRESSIN; CARDIOTONIC AGENT; VASOCONSTRICTOR AGENT;

ANAPHYLAXIS; AORTA STENOSIS; ATRIOVENTRICULAR CONDUCTION; BLOOD PRESSURE MONITORING; BRADYCARDIA; BRAIN HEMORRHAGE; BRONCHOSPASM; BRUGADA SYNDROME; CARDIOGENIC SHOCK; CARDIOPULMONARY ARREST; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIURETIC ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXTRAVASATION; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART FAILURE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMICS; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; HYPOTENSION; ISCHEMIA; LIVER TOXICITY; LOADING DRUG DOSE; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; PULMONARY ARTERY CATHETER; REVIEW; SIDE EFFECT; SUDDEN DEATH; TACHYCARDIA; THROMBOCYTOPENIA; TISSUE NECROSIS; TORSADE DES POINTES; VASOCONSTRICTION; AUTONOMIC NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; HEART MUSCLE; METABOLISM; PATHOPHYSIOLOGY; SYNDROME; VASCULAR SMOOTH MUSCLE;

AUTONOMIC NERVOUS SYSTEM; CARDIAC OUTPUT; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; SYNDROME; VASOCONSTRICTOR AGENTS;

EID: 52149085206     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.728840     Document Type: Review

References (78)

1. Abel JJ, Taveau RD. On the decomposition products of epinephrine hydrate. J Biol Chem. 1905;1:1-32.
2. Barger G, Dale HH. Chemical structure and sympathomimetic action of amines. J Physiol. 1910;41:19-59.
3. Gillies M, Bellomo R, Doolan L, Buxton B. Bench-to-bedside review: inotropic drug therapy after adult cardiac surgery: a systematic literature review. Crit Care. 2005;9:266-279.
4. Tilley DG, Rockman HA. Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. Expert Rev Cardiovasc Ther. 2006;4:417-432.
5. Li HT, Long CS, Rokosh DG, Honbo NY, Karliner JS. Chronic hypoxia differentially regulates α1-adrenergic receptor subtype mRNAs and inhibits αl-adrenergic receptor-stimulated cardiac hypertrophy and signaling. Circulation. 1995;92:918-925.
6. Modest VE, Butterworth JF IV. Effect of pH and lidocaine on beta- adrenergic receptor binding: interaction during resuscitation? Chest. 1995;108:1373-1379.
7. Denton MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int. 1996;50:4-14.
8. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J; Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Lancet. 2000;356:2139-2143.
9. Ruffolo RR Jr. The pharmacology of dobutamine. Am J Med Sci. 1987; 294:244-248.
10. Patel RN, Arteaga RB, Mandawat MK, Thornton JW, Robinson VJ. Phar- macologic stress myocardial perfusion imaging. South Med J. 2007;100:1006-1014.
11. Unverferth DA, Blanford M, Kates RE, Leier CV. Tolerance to dobuta- mine after a 72 hour continuous infusion. Am J Med. 1980;69:262-266.
12. Tune JD, Richmond KN, Gorman MW, Feigl EO. Control of coronary blood flow during exercise. Exp Biol Med (Maywoodd). 2002;227:238-250.
13. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation. 1998;98:1329-1334.
14. Jones CJ, DeFily DV, Patterson JL, Chilian WM. Endothelium-dependent relaxation competes with α1- and α2-adrenergic constriction in the canine epicardial coronary microcirculation. Circulation. 1993;87:1264-1274.
15. Singh K, Xiao L, Remondino A, Sawyer DB, Colucci WS. Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol. 2001;189:257-265.
16. Turner RA, Pierce JG, du Vigneaud V. The purification and the amino acid content of vasopressin preparations. J Biol Chem. 1951;191:21-28.
17. Hupf H, Grimm D, Riegger GA, Schunkert H. Evidence for a vasopressin system in the rat heart. Circ Res. 1999;84:365-370.
18. Guillon G, Grazzini E, Andrez M, Breton C, Trueba M, Serradeil-LeGal C, Boccara G, Derick S, Chouinard L, Gallo-Payet N. Vasopressin: a potent autocrine/paracrine regulator of mammal adrenal functions. Endocr Res. 1998;24:703-710.
19. Salzman AL, Vromen A, Denenberg A, Szabo C. K(ATP)-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock. Am J Physiol. 1997;272:H688-H694.
20. Kusano E, Tian S, Umino T, Tetsuka T, Ando Y, Asano Y. Arginine vasopressin inhibits interleukin-1 beta-stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells. J Hypertens. 1997;15:627-632.
21. Hamu Y, Kanmura Y, Tsuneyoshi I, Yoshimura N. The effects of vaso- pressin on endotoxin-induced attenuation of contractile responses in human gastroepiploic arteries in vitro. Anesth Analg. 1999;88:542-548.
22. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98:2141-2147.
23. LehtonenL, PoderP. Theutilityoflevosimendaninthetreatmentofheart failure. Ann Med. 2007;39:2-17.
24. Mukae S, Yanagishita T, Geshi E, Umetsu K, Tomita M, Itoh S, Konno N, Katagiri T. The effects of dopamine, dobutamine and amrinone on mitochondrial function in cardiogenic shock. Jpn Heart J. 1997;38:515-529.
25. Stamm C, Friehs I, Cowan DB, Cao-Danh H, Choi YH, Duebener LF, McGowan FX, del Nido PJ. Dopamine treatment of postischemic contractile dysfunction rapidly induces calcium-dependent pro-apoptotic signaling. Circulation. 2002;106(suppl I):I-290-I-298.
26. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). JAm Coll Cardiol. 2004;44:E1-E211.
27. Richard C, Ricome JL, Rimailho A, Bottineau G, Auzepy P. Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock. Circulation. 1983;67:620-626.
28. Lin H, Young DB. Opposing effects of plasma epinephrine and norepi- nephrine on coronary thrombosis in vivo. Circulation. 1995;91:1135-1142.
29. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345:588-595.
30. Sharshar T, Carlier R, Blanchard A, Feydy A, Gray F, Paillard M, Raphael JC, Gajdos P, Annane D. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med. 2002;30:497-500.
31. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes to the vasodi- lation of septic shock. Circulation. 1997;95:1122-1125.
32. Day TA, Randle JC, Renaud LP. Opposing alpha- and beta-adrenergic mechanisms mediate dose-dependent actions of noradrenaline on supraoptic vasopressin neurones in vivo. Brain Res. 1985;358:171-179.
33. Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR. Arginine vasopressin in advanced vaso- dilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107:2313-2319.
34. Okamura T, Ayajiki K, Fujioka H, Toda N. Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries. J Hypertens. 1999;17:673-678.
35. Jolly S, Newton G, Horlick E, Seidelin PH, Ross HJ, Husain M, Dzavik V. Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction. Am J Cardiol. 2005;96:1617-1620.
36. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001;142:393-401.
37. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, deMets DL; the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468-1475.
38. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. Circulation. 2003;108:492-497.
39. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112:e154-e235.
40. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure: a meta-regression analysis. Eur J Heart Fail. 2002;4:515-529.
41. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie MR, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Garcia MA, Dickstein K, Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, Janssens U, Komajda M, Morais J, Moreno R, Singer M, Singh S, Tendera M, Thygesen K. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384-416.
42. Perrino C, Rockman HA, Chiariello M. Targeted inhibition of phospho- inositide 3-kinase activity as a novel strategy to normalize beta- adrenergic receptor function in heart failure. Vascul Pharmacol. 2006; 45:77-85.
43. Karlsberg RP, DeWood MA, DeMaria AN, Berk MR, Lasher KP; Milrinone-Dobutamine Study Group. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Clin Cardiol. 1996; 19:21-30.
44. Aranda JM Jr, Schofield RS, Pauly DF, Cleeton TS, Walker TC, Monroe VS Jr, Leach D, Lopez LM, Hill JA. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J. 2003;145:324-329.
45. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422-1432.
46. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low- output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202.
47. Packer M. REVIVE II: multicentre placebo-controlled trial of levosi- mendan on clinical status in acutely decompensated heart failure. Presented at: 78th Scientific Sessions of the American Heart Association; November 13-16, 2005; Dallas, Tex.
48. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M. Levosimendan vs dobu- tamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007;297:1883-1891.
49. Hershberger RE, Nauman D, Walker TL, Dutton D, Burgess D. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail. 2003;9:180-187.
50. Fernandez-Gonzalez AL, Panizo-Santos A. Eosinophilic myocarditis in heart transplant candidates. J Heart Lung Transplant. 1996;15:852-853.
51. Sindone AP, Keogh AM, Macdonald PS, McCosker CJ, Kaan AF. Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy. Am Heart J. 1997;134:889 -900.
52. Stevenson LW, Massie BM, Francis GS. Optimizing therapy for complex or refractory heart failure: a management algorithm. Am Heart J. 1998;135:S293-S309.
53. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2005;112(suppl IV):IV-1-IV-203.
54. Paradis NA, Wenzel V, Southall J. Pressor drugs in the treatment of cardiac arrest. Cardiol Clin. 2002;20:61-78, viii.
55. Gueugniaud PY, Mols P, Goldstein P, Pham E, Dubien PY, Deweerdt C, Vergnion M, Petit P, Carli P; European Epinephrine Study Group. A comparison of repeated high doses and repeated standard doses of epi- nephrine for cardiac arrest outside the hospital. N Engl J Med. 1998;339:1595-1601.
56. Lindner KH, Strohmenger HU, Ensinger H, Hetzel WD, Ahnefeld FW, Georgieff M. Stress hormone response during and after cardiopulmonary resuscitation. Anesthesiology. 1992;77:662-668.
57. Morris DC, Dereczyk BE, Grzybowski M, Martin GB, Rivers EP, Wortsman J, Amico JA. Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation. Acad Emerg Med. 1997;4:878-883.
58. Wenzel V, Lindner KH, Prengel AW, Maier C, Voelckel W, Lurie KG, Strohmenger HU. Vasopressin improves vital organ blood flow after prolonged cardiac arrest with postcountershock pulseless electrical activity in pigs. Crit Care Med. 1999;27:486-492.
59. Lindner KH, Dirks B, Strohmenger HU, Prengel AW, Lindner IM, Lurie KG. Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet. 1997;349:535-537.
60. Wenzel V, Krismer AC, Arntz HR, Sitter H, Stadlbauer KH, Lindner KH. A comparison of vasopressin and epinephrine for out-of-hospital cardio-pulmonary resuscitation. N Engl J Med. 2004;350:105-113.
61. Kikura M, Sato S. The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesth Analg. 2002;94:22-30.
62. Omae T, Kakihana Y, Mastunaga A, Tsuneyoshi I, Kawasaki K, Kanmura Y, Sakata R. Hemodynamic changes during off-pump coronary artery bypass anastomosis in patients with coexisting mitral regurgitation: improvement with milrinone. Anesth Analg. 2005;101:2-8.
63. Feneck RO, Sherry KM, Withington PS, Oduro-Dominah A. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. J Cardiothorac Vasc Anesth. 2001;15:306-315.
64. Byrne JG, Leacche M, Paul S, Mihaljevic T, Rawn JD, Shernan SK, Mudge GH, Stevenson LW. Risk factors and outcomes for "vasoplegia syndrome" following cardiac transplantation. Eur J Cardiothorac Surg. 2004;25:327-332.
65. Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD, Smith CR Jr, Rose EA, Landry DW, Oz MC. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg. 1998;116:973-980.
66. Ozal E, Kuralay E, Yildirim V, Kilic S, Bolcal C, Kucukarslan N, Gunay C, Demirkilic U, Tatar H. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg. 2005;79:1615-1619.
67. Morales DL, Garrido MJ, Madigan JD, Helman DN, Faber J, Williams MR, Landry DW, Oz MC. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg. 2003;75:926-930.
68. Dell'Italia LJ. Reperfusion for right ventricular infarction. N Engl J Med. 1998;338:978 -980.
69. Calvin JE Jr. Acute right heart failure: pathophysiology, recognition, and pharmacological management. J Cardiothorac Vasc Anesth. 1991;5:507-513.
70. Goldstein JA. Pathophysiology and management of right heart ischemia. J Am Coll Cardiol. 2002;40:841-853.
71. Ferrario M, Poli A, Previtali M, Lanzarini L, Fetiveau R, Diotallevi P, Mussini A, Montemartini C. Hemodynamics of volume loading compared with dobutamine in severe right ventricular infarction. Am J Cardiol. 1994;74:329 -333.
72. Marquez MF, Salica G, Hermosillo AG, Pastelin G, Cardenas M. Drug therapy in Brugada syndrome. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:409-417.
73. Summerhill EM, Baram M. Principles ofpulmonary artery catheterization in the critically ill. Lung. 2005;183:209-219.
74. Shah MR, Hasselblad V, Stevenson LW, Binanay C, O'Connor CM, Sopko G, Califf RM. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA. 2005;294:1664-1670.
75. Binanay C, CaliffRM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294:1625-1633.
76. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med. 1994;330:1717-1722.
77. Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington RA, Van de Werf F, Hochman JS. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007;297:1657-1666.
78. Dzavik V, Cotter G, Reynolds HR, Alexander JH, Ramanathan K, Stebbins AL, Hathaway D, Farkouh ME, Ohman EM, Baran DA, Prondzinsky R, Panza JA, Cantor WJ, Vered Z, Buller CE, Kleiman NS, Webb JG, Holmes DR, Parrillo JE, Hazen SL, Gross SS, Harrington RA, Hochman JS. Effect of nitric oxide synthase inhibition on haemody- namics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur Heart J. 2007;28:1109-1116. drugs ,heart failure ,inotropic agents ,shock ,vasopressin